Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KANAGARATNAM SIVALINGAM

Allopathic & Osteopathic Physicians Internal Medicine Geriatric Medicine

NPI
1578578365
CMS profile
70616
Location
LANCASTER, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,810.40

87 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,810.40 87

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KANAGARATNAM SIVALINGAM

NPI 1578578365 · CMS profile ID 70616

Allopathic & Osteopathic Physicians / Internal Medicine / Geriatric Medicine

LANCASTER, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578578365?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KANAGARATNAM SIVALINGAM, NPI 1578578365, CMS profile ID 70616. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578578365?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). KANAGARATNAM SIVALINGAM, NPI 1578578365, CMS profile ID 70616. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578578365?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
KANAGARATNAM SIVALINGAM, NPI 1578578365, CMS profile ID 70616, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578578365?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

87 matching records · $1,810.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 87 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–87 of 87.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $10.1805/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826371535 CMS
AstraZeneca Pharmaceuticals LP $15.1305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829987993 CMS
Novo Nordisk Inc $11.4405/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810870421 CMS
Novo Nordisk Inc $12.9005/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811046829 CMS
Mylan Specialty L.P. $13.8305/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965416039 CMS
Sunovion Pharmaceuticals Inc. $15.8705/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821791825 CMS
GlaxoSmithKline, LLC. $12.4605/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802200209 CMS
Amarin Pharma Inc. $19.7905/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815159187 CMS
Abbott Laboratories $14.7905/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815621599 CMS
RedHill Biopharma Inc. $18.7805/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799946031 CMS
Xeris Pharmaceuticals, Inc. $18.8705/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837445951 CMS
Biohaven Pharmaceuticals, Inc. $16.9004/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852627701 CMS
Ironwood Pharmaceuticals, Inc $28.9904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855127825 CMS
Novo Nordisk Inc $24.9304/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811046819 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.4304/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763623378 CMS
Horizon Therapeutics plc $19.9804/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797209633 CMS
AbbVie Inc. $22.8303/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796053815 CMS
Amgen Inc. $30.2903/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825491081 CMS
Esperion Therapeutics, Inc. $26.9203/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838408375 CMS
AbbVie Inc. $9.4803/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796053813 CMS
GlaxoSmithKline, LLC. $13.2403/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801637225 CMS
Alnylam Pharmaceuticals Inc. $27.0003/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828514397 CMS
Amgen Inc. $29.2203/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825491117 CMS
ARBOR PHARMACEUTICALS, INC. $16.2203/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830939205 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.6903/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763623380 CMS
Horizon Therapeutics plc $23.8503/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797209629 CMS
Merck Sharp & Dohme Corporation $17.7203/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848708617 CMS
Amgen Inc. $8.7303/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825491111 CMS
AbbVie Inc. $17.7202/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796053811 CMS
Horizon Therapeutics plc $19.8902/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797209627 CMS
Janssen Pharmaceuticals, Inc $23.7802/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788404359 CMS
Amgen Inc. $14.7401/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825491105 CMS
AbbVie Inc. $5.3101/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796053809 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $32.8201/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763623382 CMS
GlaxoSmithKline, LLC. $16.4101/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803117391 CMS
Abbott Laboratories $22.2701/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818392969 CMS
RedHill Biopharma Inc. $18.9901/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799946029 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $775.69 47
PY2020 $628.31 33
PY2021 $1,810.40 87
PY2022 $1,504.54 68
PY2023 $759.87 42
PY2024 $562.00 26
PY2025 $351.76 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $139.54 1
PY2025 Principal investigator $430,140.40 18
PY2024 Recipient $20,134.13 3
PY2024 Principal investigator $214,365.94 122
PY2023 Recipient $413.78 2
PY2023 Principal investigator $249,691.67 581
PY2022 Recipient $194.00 2
PY2022 Principal investigator $167,107.99 356
PY2021 Recipient $61.43 1
PY2021 Principal investigator $198,187.55 304
PY2020 Recipient $328.00 1
PY2020 Principal investigator $285,164.03 430
PY2019 Recipient $7,512.91 3
PY2019 Principal investigator $842,462.65 363

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735588
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735586
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735584
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 09/19/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220997426
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735582
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $254.88 08/19/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220809229
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $136.64 08/18/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220809227
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735574
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735576
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735578
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
First Valley Medical Group-Dr Kanagaratnam Sivalingam
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735580
Recipient Eli Lilly and Company $139.54 04/10/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187872455
Principal investigator 1 Novo Nordisk AS $20,704.98 03/31/2025 Non-covered Recipient Entity
FIRST VALLEY MEDICAL GROUP
EX9924-4473 No dispute reported 06/30/2026 1213714091
Principal investigator 1 Eli Lilly and Company $528.08 02/11/2025 Non-covered Recipient Entity
SIVALINGAM MEDICAL CORPORATION INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187889370
Principal investigator 1 Eli Lilly and Company $847.41 02/11/2025 Non-covered Recipient Entity
SIVALINGAM MEDICAL CORPORATION INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187889372
Principal investigator 1 Eli Lilly and Company $8,964.26 02/07/2025 Non-covered Recipient Entity
SIVALINGAM MEDICAL CORPORATION INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187889990
Principal investigator 1 Eli Lilly and Company $69,800.00 01/21/2025 Non-covered Recipient Entity
SIVALINGAM MEDICAL CORPORATION INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187889374
Principal investigator 1 Eli Lilly and Company $26,874.00 01/21/2025 Non-covered Recipient Entity
SIVALINGAM MEDICAL CORPORATION INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187890510
Principal investigator 1 Eli Lilly and Company $294,981.00 01/07/2025 Non-covered Recipient Entity
SIVALINGAM MEDICAL CORPORATION INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187888268